Portal de Periódicos da CAPES

Nontuberculous mycobacterial pulmonary disease: an increasing burden with substantial costs

2017; European Respiratory Society; Volume: 49; Issue: 4 Linguagem: Inglês

10.1183/13993003.00374-2017

1399-3003

D. Rebecca Prevots, R. Loddenkemper, Giovanni Sotgiu, Giovanni Battista Migliori,

Gastric Cancer Management and Outcomes

Increased awareness of nontuberculous mycobacterial pulmonary disease (NTM PD) has led to efforts to more fully describe the burden, epidemiological and clinical features, and cost of this condition in different populations globally. Approaches encompass various methodologies including surveillance, population-based studies, analysis of large linked datasets, surveys, laboratory-based convenience samples and combinations of these approaches. Surveillance has been defined as the "systematic collection, consolidation, and evaluation of morbidity and mortality reports, and… regular dissemination to all who need to know" [1]. For NTM PD, notifiable condition reporting varies. In Queensland, Australia, notification of NTM infections is required; reporting is electronic and laboratory-based [2]. In several states within the USA, NTM isolates or cases are listed as notifiable conditions [3, 4], although in Oregon, only extrapulmonary isolates are listed as notifiable [3]. Although reporting might not be complete, and the system may have biases related to healthcare-seeking behaviour and physician awareness, these data are essential to elucidating the epidemiology of NTM PD [3]. The cost of nontuberculous mycobacterial pulmonary disease is substantial, with high hospitalisation and drug costs